Subcutaneous amivantamab induced rapid and durable responses among patients with HPV-unrelated recurrent or metastatic head and neck cancer, according to study results.Nearly half of patients responded to therapy and more than three-quarters experienced shrinkage of target lesions, findings presented at ASCO Annual Meeting and published simultaneously in Journal of Clinical Oncology showed.“These results are very meaningful,” senior author Barbara Burtness,…
Source: Healio News
